OR-AIRSHIP
7.4.2022 10:02:06 CEST | Business Wire | Press release
Airship , the mobile app experience company, today announced the launch of its App Experience Platform (AXP), the only enterprise SaaS platform focused on helping brands master the full lifecycle of mobile app experience (MAX) management. AXP aims to address the ongoing challenge for brands to treat their apps as a high-value destination rather than simply a promotional messaging channel.
Mobile apps have become the centre of the digital customer experience — generating more than three times greater revenue and transaction frequency compared to other channels. Yet, according to data derived from Apptopia, app user retention rates have barely increased over the last three years, despite ongoing growth in annual worldwide app downloads.
AXP enables product, digital and marketing teams to create, refine and publish no-code native app experiences on their own without ongoing developer support or app updates. As a result, it vastly improves the continuous onboarding, retention and first party and zero-party data collection of customers. This new SaaS platform also unifies the native app experiences, customer journey orchestration and app UX experimentation with no-code approaches and intuitive visual UIs, freeing development teams to innovate market-differentiating app features.
Brett Caine, CEO and President at Airship, said : “Messaging only goes so far in helping to retain and monetise app users. Brands must provide valuable and relevant experiences in the moments people are engaged with the app to create reciprocal value exchanges necessary for sustained relationships .” He added: “With AXP, we’re giving brands unparalleled agility to grow user understanding and provide app experiences that reward customers for their loyalty .”
More than 15 leading brands gained early access to new AXP innovations such as AXP Mobile Data Hub, AXP Scenes, AXP Surveys and AXP Preference Center to evaluate and test the benefit to their businesses and provide feedback for ongoing refinement.
Joseph Brooks, Head of Product, Shell plc, one of Airship’s customers, said: “The Shell app is the centrepiece of our customers’ mobility experience, allowing them to pay and save in one easy step. With Airship’s real-time notifications and in-app automation we’ve increased our retention rate 3X and grown our active user base by 3.5X . The new capabilities in Airship’s App Experience Platform will help to dramatically accelerate our time-to-market and agility in optimising user onboarding and collecting in-app feedback from users to continue to improve their app experience .”
Michael Lowe, Vice President, Digital Strategy & Partnerships at NBC Sports Group, another of Airship’s customers, added: “Sports fans demand the best, most personalised in-the-moment app experiences, and it’s a requirement for our teams to look for opportunities for continued innovation that facilitates new user onboarding, drives new feature adoption, introduces new content franchises, and elicits valuable user feedback. Airship’s App Experience Platform provides us with new capabilities that save valuable product development time and give our team faster ways to optimise each fan’s journey .”
According to Forrester Research, Inc.’s, August 2021 report “Make Marketing More Than A Message ”: “The best brand experiences connect to customers in critical moments, not just at a channel level. Pulling off this level of personalisation requires that brands design for moments first … Marketers are innovating across critical facets of business (not just with media and messaging) by shaping the entire experience to differentiate their brand in the eyes of their customers .”
For the latest information on consumer privacy attitudes, preferences and behaviours, and how brands can create a trusted exchange with their customers, register for an April 14th webinar featuring guest speaker Stephanie Liu, Analyst, Forrester Research, Inc., and Mike Herrick, SVP of Technology, Airship.
For more detail on this announcement, please access ungated eBooks on MAX and AXP .
Additional Customer Quotes:
“Our entire team was both surprised and delighted by Airship’s new App Experience Platform ,” said Laurent Claramonte, head of data analytics for Products and Mobile Apps at Orange France . “With more than 10 apps in total, including TV, Smart Home and Messaging apps like Orange TV or Orange Mail, new capabilities like AXP Scenes free our developers to focus on new innovations as our product owners now have full autonomy to continually optimise native, multi-screen experiences that drive feature adoption. AXP is a game-changer, allowing us to go far beyond promotional and messaging-based approaches to drive better app onboarding and retention, and achieve greater customer satisfaction and loyalty .”
“As the most popular football media platform in the world, OneFootball is constantly adding new features, products and content to provide an immersive and fully personalised experience to more than 100 million football fans monthly ,” said Ismail Elshareef, Chief Product Officer at OneFootball . “With AXP Scenes and Surveys we can provide fans with better onboarding to these new experiences, collect more information upfront for greater personalization, and better inform future development to ensure our customers get exactly what they want from OneFootball .”
About Airship
No one knows more, does more, or cares more when it comes to helping brands master mobile app experiences than Airship.
From the beginning of apps, Airship powered the first commercial messages and then expanded its data-led approach to all re-engagement channels (mobile wallet, SMS, email), app UX experimentation and feature release management. Now, with the Airship App Experience Platform (AXP), business users can create and adapt native app experiences on their own — with no ongoing developer support or app update required.
Having powered trillions of mobile app interactions for thousands of global brands, Airship’s technology and deep industry expertise have enabled apps to become the digital centre of customer experience, brand loyalty and monetisation.
For more information, visit www.airship.com , read our blog or follow us on Twitter , LinkedIn and Facebook .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220406006111/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom